{
    "xml": "<topic id=\"PHP665\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/methylnaltrexone-bromide\" basename=\"methylnaltrexone-bromide\" title=\"METHYLNALTREXONE BROMIDE\">\n<title>METHYLNALTREXONE BROMIDE</title>\n<body>\n<data name=\"vtmid\">13807711000001105</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_220784242\" title=\"Opioid receptor antagonists (peripheral)\">Opioid receptor antagonists (peripheral)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP52572\" outputclass=\"drugAction\" rev=\"1.18\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Peripherally acting opioid-receptor antagonist which does not alter the central analgesic effect of opioids.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52275\" outputclass=\"indicationsAndDose\" rev=\"1.44\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunct to other laxatives in opioid-induced constipation in terminally ill patients, when response to other laxatives is inadequate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight up to 38 kg)</p>\n<p>150&#8239;micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 38&#8211;62 kg)</p>\n<p>8&#8239;mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 62&#8211;114 kg)</p>\n<p>12&#8239;mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 115 kg and above)</p>\n<p>150&#8239;micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"pharmacokinetics\">\n<title>Pharmacokinetics</title>\n<p>May act with 30&#8211;60 minutes.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52649\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Acute surgical abdominal conditions</ph>; <ph outputclass=\"contraindication\">gastro-intestinal obstruction</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52733\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diverticular disease</ph>; <ph outputclass=\"caution\">faecal impaction</ph>; <ph outputclass=\"caution\">patients with colostomy</ph>; <ph outputclass=\"caution\">patients with peritoneal catheter</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51510\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">flatulence</ph>; <ph outputclass=\"sideEffect\">hyperhidrosis</ph>; <ph outputclass=\"sideEffect\">injection site reactions</ph>; <ph outputclass=\"sideEffect\">nausea</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Gastro-intestinal perforation</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52083\" outputclass=\"pregnancy\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Toxicity at high doses in <i>animal</i> studies&#8212;manufacturer advises avoid unless essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52770\" outputclass=\"breastFeeding\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52337\" outputclass=\"hepaticImpairment\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid in severe hepatic impairment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51789\" outputclass=\"renalImpairment\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>If eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, reduce dose as follows: body-weight under 62&#8239;kg, 75&#8239;micrograms/kg on alternate days; body-weight 62&#8211;114&#8239;kg, 8&#8239;mg on alternate days; body-weight over 114&#8239;kg, 75&#8239;micrograms/kg on alternate days.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52845\" outputclass=\"directionsForAdministration\" rev=\"1.8\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Rotate injection site.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP665-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/methylnaltrexone-bromide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77002\" title=\"Solution for injection\" namespace=\"/drugs/methylnaltrexone-bromide/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"1\" rel=\"backlink\">Prescribing in palliative care</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77002\" namespace=\"/drugs/methylnaltrexone-bromide/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP665",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/methylnaltrexone-bromide",
    "basename": "methylnaltrexone-bromide",
    "title": "METHYLNALTREXONE BROMIDE",
    "vtmid": "13807711000001105",
    "drugClassification": [
        "Opioid receptor antagonists (peripheral)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Peripherally acting opioid-receptor antagonist which does not alter the central analgesic effect of opioids.",
                "html": "<p>Peripherally acting opioid-receptor antagonist which does not alter the central analgesic effect of opioids.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Adjunct to other laxatives in opioid-induced constipation in terminally ill patients, when response to other laxatives is inadequate",
                        "html": "Adjunct to other laxatives in opioid-induced constipation in terminally ill patients, when response to other laxatives is inadequate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "150 micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.",
                        "html": "<p>150&#8239;micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>",
                        "ageGroup": "(body-weight up to 38 kg)"
                    },
                    {
                        "textContent": "8 mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.",
                        "html": "<p>8&#8239;mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>",
                        "ageGroup": "(body-weight 38&#8211;62 kg)"
                    },
                    {
                        "textContent": "12 mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.",
                        "html": "<p>12&#8239;mg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>",
                        "ageGroup": "(body-weight 62&#8211;114 kg)"
                    },
                    {
                        "textContent": "150 micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.",
                        "html": "<p>150&#8239;micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, may be given less frequently depending on response; 2 consecutive doses may be given 24 hours apart if no response to treatment on the preceding day.</p>",
                        "ageGroup": "(body-weight 115 kg and above)"
                    }
                ]
            }
        ],
        "pharmacokinetics": [
            {
                "type": "pharmacokinetics",
                "title": "Pharmacokinetics",
                "textContent": "May act with 30&#8211;60 minutes.",
                "html": "<p>May act with 30&#8211;60 minutes.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Acute surgical abdominal conditions",
                "html": "Acute surgical abdominal conditions"
            },
            {
                "type": "contraindications",
                "textContent": "gastro-intestinal obstruction",
                "html": "gastro-intestinal obstruction"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diverticular disease",
                "html": "Diverticular disease"
            },
            {
                "type": "cautions",
                "textContent": "faecal impaction",
                "html": "faecal impaction"
            },
            {
                "type": "cautions",
                "textContent": "patients with colostomy",
                "html": "patients with colostomy"
            },
            {
                "type": "cautions",
                "textContent": "patients with peritoneal catheter",
                "html": "patients with peritoneal catheter"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flatulence",
                        "html": "flatulence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperhidrosis",
                        "html": "hyperhidrosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "injection site reactions",
                        "html": "injection site reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Gastro-intestinal perforation",
                        "html": "Gastro-intestinal perforation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Toxicity at high doses in animal studies&#8212;manufacturer advises avoid unless essential.",
                "html": "<p>Toxicity at high doses in <i>animal</i> studies&#8212;manufacturer advises avoid unless essential.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid in severe hepatic impairment&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid in severe hepatic impairment&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "If eGFR less than 30 mL/minute/1.73 m2, reduce dose as follows: body-weight under 62 kg, 75 micrograms/kg on alternate days; body-weight 62&#8211;114 kg, 8 mg on alternate days; body-weight over 114 kg, 75 micrograms/kg on alternate days.",
                "html": "<p>If eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, reduce dose as follows: body-weight under 62&#8239;kg, 75&#8239;micrograms/kg on alternate days; body-weight 62&#8211;114&#8239;kg, 8&#8239;mg on alternate days; body-weight over 114&#8239;kg, 75&#8239;micrograms/kg on alternate days.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Rotate injection site.",
                "html": "<p>Rotate injection site.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77002",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77002",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}